IDEAYA Biosciences Enrolls First Patient in Phase 1/2 Combination Trial of IDE397 and Trodelvy® in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...
